These findings supported previous reports from Wiggins et al. and Zschiedrich et al. who proposed a stage-based functional limit to podocyte hypertrophy and a narrow therapeutic window for effective mTOR inhibition in FSGS respectively (Wiggins et al. 2005; Zschiedrich et al. 2017). Here, MTOR is linked to focal segmental glomerulosclerosis.